BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 26980746)

  • 1. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
    Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Pinzòn-Daza ML; Giordano A; Desiderio V; Ghigo D; De Rosa G; Caraglia M; Riganti C
    Oncotarget; 2016 Apr; 7(15):20753-72. PubMed ID: 26980746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.
    Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Giordano A; Desiderio V; Ghigo D; Caraglia M; De Rosa G; Riganti C
    Oncotarget; 2015 Oct; 6(31):31461-78. PubMed ID: 26372812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.
    Salaroglio IC; Campia I; Kopecka J; Gazzano E; Orecchia S; Ghigo D; Riganti C
    Oncotarget; 2015 Jan; 6(2):1128-42. PubMed ID: 25544757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.
    Belisario DC; Akman M; Godel M; Campani V; Patrizio MP; Scotti L; Hattinger CM; De Rosa G; Donadelli M; Serra M; Kopecka J; Riganti C
    Cells; 2020 Mar; 9(3):. PubMed ID: 32155954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.
    Riganti C; Castella B; Kopecka J; Campia I; Coscia M; Pescarmona G; Bosia A; Ghigo D; Massaia M
    PLoS One; 2013; 8(4):e60975. PubMed ID: 23593363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
    Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
    Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
    Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
    Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells.
    Kars MD; Işeri OD; Ural AU; Gündüz U
    Anticancer Res; 2007; 27(6B):4031-7. PubMed ID: 18225567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
    Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
    Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity.
    Amini MA; Abbasi AZ; Cai P; Lip H; Gordijo CR; Li J; Chen B; Zhang L; Rauth AM; Wu XY
    J Natl Cancer Inst; 2019 Apr; 111(4):399-408. PubMed ID: 30239773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
    Ottewell PD; Lefley DV; Cross SS; Evans CA; Coleman RE; Holen I
    Int J Cancer; 2010 Jan; 126(2):522-32. PubMed ID: 19621384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
    Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
    J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
    Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
    Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
    Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
    Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.